Slide 1: Myriad Genetics myChoice HRD Update
Myriad Genetics myChoice HRD® Update 06/30/2016 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: A Pioneering Discovery: myChoice HRD
A Pioneering Discovery: myChoice HRD
Slide 4: PARP Mechanism of Action
PARP Mechanism of Action Normal Cell Deficient Cell
Slide 5: Homologous Recombination (HR) Pathway Status Predicts Drug Response
Homologous Recombination (HR) Pathway Status Predicts Drug Response When the HR pathway is working properly, DNA can be repaired effectively and is error free, maintaining genomic stability When the HR pathway is disrupted by gene mutations, promoter methylation or unknown causes, the HR pathway sto
Slide 6: Most Causes of Homologous Recombination Deficiency (HRD) Are Unknown
Most Causes of Homologous Recombination Deficiency (HRD) Are Unknown When the HR pathway is disrupted by gene mutations, promoter methylation or unidentified causes, the HR pathway stops working leading Homologous Recombination Deficiency or HRD Tumors with HRD are unable to repair themselves effect
Slide 7: Pioneering Discovery: Measure the Effects vs. the Causes
The Cause? Lane closure? Traffic light failure? Overturned truck? Fender bender? Presidential motorcade? Who cares…. Pioneering Discovery: Measure the Effects vs. the Causes The EFFECT…..
Slide 8: Measuring the DNA "Scar" – With Proprietary Informatics
Measuring the DNA “Scar” – With Proprietary Informatics myChoice HRD Negative (myChoice HRD Score = 3) myChoice HRD Positive (myChoice HRD Score = 81) Genome profiles are pictures of instability in tumor DNA Cutoff = 42 genomic instability caused by HRD
Slide 9: myChoice HRD Identifies the Most Patients with Ovarian Cancer Potentially Eligible for a Drug
myChoice HRD Identifies the Most Patients with Ovarian Cancer Potentially Eligible for a Drug 15% of patients are positive for BRACAnalysis CDx1 22% of patients are positive for Tumor BRACAnalysis CDx2 ≈25% of patients are positive for a broad tumor HR panel3 ≈50% of patients are positive for myChoi
Slide 10: Comprehensive Tumor Profiling Identifies Few Additional HRD Patients
Comprehensive Tumor Profiling Identifies Few Additional HRD Patients AstraZeneca Study 19: 135 patients with tumor mutations as profiled with 315 gene Foundation Medicine Panel Only 4 genes mutated more than once Only 12 genes had any mutations
Slide 11: Portfolio of Tests for Assessing DNA Repair Pathway
Portfolio of Tests for Assessing DNA Repair Pathway Tumor Panel Sample Blood Tumor Tumor Tumor Biomarkers BRCA1&2 Tumor BRCA1&2 80+ clinically actionable oncology genes identified by pharma partners Genome-wide assessment of DNA scar associated with DNA repair defects Intellectual Property Database,
Slide 12: myChoice HRD Score Results From the Combined Analysis of Three Different Biomarkers
myChoice HRD Score Results From the Combined Analysis of Three Different Biomarkers myChoice HRD Score Loss of Heterozygosity (LOH) Telomeric Allelic Imbalance (TAI) Large-Scale State Transitions (LST)
Slide 13: Three Biomarkers Result in a More Discriminating Measurement of HRD
Three Biomarkers Result in a More Discriminating Measurement of HRD Loss of heterozygosity (LOH) Telomeric allelic imbalance (TAI) Large-scale state transitions (LST) Presence of a single allele A discrepancy in the 1:1 allele ratio at the end of the chromosome (telomere) Transition points between r
Slide 14: Single Measures of HRD are Insufficient
Single Measures of HRD are Insufficient Hennessy BT, et al. J Clin Oncol. 2010; 28:3570. TCGA Research Network. Nature. 2011; 474:6609. Bannerjee et al. Ann Oncol. 2013;24(3):679. In a cohort of 859 ovarian tumors, only a combination of all three biomarkers (HRD score) yielded a clear cutoff.
Slide 15: NOVA Study and Data
e - NOVAStudy andData® @
Slide 16: Review of the NOVA Study
Review of the NOVA Study Phase 3 NOVA Trial High-Grade Serous Ovarian Cancer, Platinum Sensitive, Relapsed Response to Platinum Treatment N=490 gBRCAmut Non-gBRCAmut / HRD 2:1 Randomization 2:1 Randomization Niraparib 300mg Niraparib 300mg Placebo Placebo Endpoint Assessment Endpoint Assessment myCh
Slide 17: Niraparib Highly Efficacious in Both myChoice HRD+ Patients and Germline BRCA+ Patients
Niraparib Highly Efficacious in Both myChoice HRD+ Patients and Germline BRCA+ Patients p<0.0001 ? 21.0 Progression Free Survival (Months) p<0.0001
Slide 18: Summary of the NOVA Data
Summary of the NOVA Data Niraparib is highly effective in patients with germline BRCA mutations and those with myChoice HRD positive test results myChoice HRD identifies ≈2x as many patients who would benefit from Niraparib compared to the FDA approved BRACAnalysis CDx test. The myChoice HRD+ patien
Slide 19: Business Impact
Business Impact
Slide 20: Extensive Collaborations With >22 Clinical Studies
Extensive Collaborations With >22 Clinical Studies NSCLC (240,000) Global Market > 1.4M patients or $6.0b* Neoadjuvant BC (143,000) Ovarian (60,000) Platinum in Her2-BC (120,000) FY15 FY16 FY17 FY18 FY19 FY20 *Includes U.S., Canada and EU6 Platinum in TNBC (95,000) Pancreatic (102,000) Metastatic Pr
Slide 21: myChoice HRD Addressable Market in Ovarian Cancer
myChoice HRD Addressable Market in Ovarian Cancer U.S. 22,000 patients EU5 & Canada 38,000 patients Differentiated diagnostic that is strategically important to pharma Protected by strong intellectual property with both patents and trade secrets Unlike BRACAnalysis CDx, this is an additive opportuni
Slide 22: myChoice HRD is Additive To Hereditary Cancer Testing
myChoice HRD is Additive To Hereditary Cancer Testing Tumor BRCA+ Single site confirmation test Tumor BRCA- % Patients ≈20% ≈30% ≈50%
Slide 23: Revenue Curve for Companion Diagnostics is Much Steeper Than for Traditional Diagnostics
Revenue Curve for Companion Diagnostics is Much Steeper Than for Traditional Diagnostics Market Penetration Time Broad Reimbursement Obtained Companion Diagnostic Traditional Diagnostic
Slide 24: Other Strategic Considerations
Other Strategic Considerations First prospective data and major validation of myChoice HRD – reduces risk for pharma partners and likely drives additional collaborations Growing core competency in FDA approved, high-value companion diagnostics Intellectual property around myChoice HRD is significant